Safety signals of zolbetuximab in gastric or gastroesophageal junction adenocarcinoma: a comprehensive analysis of the FDA adverse event reporting system (FAERS) data - Scorecard - MDSpire
Advertisement
Safety signals of zolbetuximab in gastric or gastroesophageal junction adenocarcinoma: a comprehensive analysis of the FDA adverse event reporting system (FAERS) data
Clinical Scorecard: Evaluation of Safety Signals for Zolbetuximab in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: An In-Depth Review of FAERS Data
At a Glance
Category
Detail
Condition
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Key Mechanisms
Monoclonal antibody targeting CLDN18.2, mediating tumor cell killing via ADCC and CDC.
Target Population
Patients with advanced gastric or gastroesophageal junction adenocarcinoma.
Care Setting
Post-marketing pharmacovigilance.
Key Highlights
Study highlights the importance of post-marketing surveillance.
Guideline-Based Recommendations
Diagnosis
Monitor for gastrointestinal and metabolic disorders in patients receiving zolbetuximab.
Management
Consider potential unlabeled adverse events when prescribing zolbetuximab.
Monitoring & Follow-up
Conduct regular assessments for adverse events, especially within the first month of treatment.
Risks
Be aware of the potential for gastritis, protein-losing gastroenteropathy, and other identified adverse events.
Patient & Prescribing Data
Zolbetuximab requires careful monitoring for adverse events.
Clinical Best Practices
Utilize the FAERS database for ongoing safety signal detection.
Implement a standardized protocol for monitoring adverse events in patients treated with zolbetuximab.
